<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30244975</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>07</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1932-7420</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>28</Volume>                    <Issue>5</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>06</Day>                    </PubDate>                </JournalIssue>                <Title>Cell metabolism</Title>                <ISOAbbreviation>Cell Metab.</ISOAbbreviation>            </Journal>            <ArticleTitle>Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>679-688.e4</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S1550-4131(18)30522-9</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmet.2018.08.021</ELocationID>            <Abstract>                <AbstractText>Late-phase clinical trials investigating metformin as a cancer therapy are underway. However, there remains controversy as to the mode of action of metformin in tumors at clinical doses. We conducted a clinical study integrating measurement of markers of systemic metabolism, dynamic FDG-PET-CT, transcriptomics, and metabolomics at paired time points to profile the bioactivity of metformin in primary breast cancer. We show metformin reduces the levels of mitochondrial metabolites, activates multiple mitochondrial metabolic pathways, and increases 18-FDG flux in tumors. Two tumor groups are identified with distinct metabolic responses, an OXPHOS transcriptional response (OTR) group for which there is an increase in OXPHOS gene transcription and an FDG response group with increased 18-FDG uptake. Increase in proliferation, as measured by a validated proliferation signature, suggested that patients in the OTR group were resistant to metformin treatment. We conclude that mitochondrial response to metformin in primary breast cancer may define anti-tumor effect.</AbstractText>                <CopyrightInformation>Crown Copyright Â© 2018. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Lord</LastName>                    <ForeName>Simon R</ForeName>                    <Initials>SR</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK; Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford OX3 7LE, UK. Electronic address: simon.lord@oncology.ox.ac.uk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cheng</LastName>                    <ForeName>Wei-Chen</ForeName>                    <Initials>WC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Dan</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gaude</LastName>                    <ForeName>Edoardo</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge CB2 0XZ, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Haider</LastName>                    <ForeName>Syed</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Breast Cancer Now Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Metcalf</LastName>                    <ForeName>Tom</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Translational Medicine, University of Liverpool, Royal Liverpool University Hospital, Liverpool L69 3GA, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Patel</LastName>                    <ForeName>Neel</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Teoh</LastName>                    <ForeName>Eugene J</ForeName>                    <Initials>EJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK; Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK; Department of Nuclear Medicine, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gleeson</LastName>                    <ForeName>Fergus</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford OX3 7LE, UK; Department of Nuclear Medicine, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bradley</LastName>                    <ForeName>Kevin</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wigfield</LastName>                    <ForeName>Simon</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zois</LastName>                    <ForeName>Christos</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McGowan</LastName>                    <ForeName>Daniel R</ForeName>                    <Initials>DR</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ah-See</LastName>                    <ForeName>Mei-Lin</ForeName>                    <Initials>ML</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Luton and Dunstable Hospital, Luton, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thompson</LastName>                    <ForeName>Alastair M</ForeName>                    <Initials>AM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgical Oncology, MD Anderson Cancer Centre, Houston, TX 77030, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sharma</LastName>                    <ForeName>Anand</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK; Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bidaut</LastName>                    <ForeName>Luc</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>College of Science, University of Lincoln, Lincoln LN6 7TS, UK; Clinical Research Imaging Facility, University of Dundee, Ninewells Hospital, Dundee DD2 1SY, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pollak</LastName>                    <ForeName>Michael</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, McGill University, Montreal, QC H3T 1E2, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Roy</LastName>                    <ForeName>Pankaj G</ForeName>                    <Initials>PG</Initials>                    <AffiliationInfo>                        <Affiliation>Breast Surgery Unit, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Karpe</LastName>                    <ForeName>Fredrik</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>James</LastName>                    <ForeName>Tim</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 9DU, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>English</LastName>                    <ForeName>Ruth</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Oxford Breast Imaging Centre, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Adams</LastName>                    <ForeName>Rosie F</ForeName>                    <Initials>RF</Initials>                    <AffiliationInfo>                        <Affiliation>Oxford Breast Imaging Centre, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Campo</LastName>                    <ForeName>Leticia</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ayers</LastName>                    <ForeName>Lisa</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical and Laboratory Immunology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Snell</LastName>                    <ForeName>Cameron</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Anatomical Pathology, Mater Research Institute, Brisbane 4101, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Roxanis</LastName>                    <ForeName>Ioannis</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 9DU, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Frezza</LastName>                    <ForeName>Christian</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge CB2 0XZ, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fenwick</LastName>                    <ForeName>John D</ForeName>                    <Initials>JD</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Translational Medicine, University of Liverpool, Royal Liverpool University Hospital, Liverpool L69 3GA, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Buffa</LastName>                    <ForeName>Francesca M</ForeName>                    <Initials>FM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Harris</LastName>                    <ForeName>Adrian L</ForeName>                    <Initials>AL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK; Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford OX3 7LE, UK.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>20</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Cell Metab</MedlineTA>            <NlmUniqueID>101233170</NlmUniqueID>            <ISSNLinking>1550-4131</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">cancer metabolism</Keyword>            <Keyword MajorTopicYN="N">clinical study</Keyword>            <Keyword MajorTopicYN="N">gene expression profiling</Keyword>            <Keyword MajorTopicYN="N">metabolomics</Keyword>            <Keyword MajorTopicYN="N">metformin</Keyword>            <Keyword MajorTopicYN="N">mitochondria</Keyword>            <Keyword MajorTopicYN="N">positron emission tomography</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>10</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>04</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30244975</ArticleId>            <ArticleId IdType="pii">S1550-4131(18)30522-9</ArticleId>            <ArticleId IdType="doi">10.1016/j.cmet.2018.08.021</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>